Comparison of the immunogenicity of five COVID‐19 vaccines in Sri Lanka
To determine the antibody responses elicited by different vaccines against SARS‐CoV‐2, we compared antibody responses in individuals 3 months post‐vaccination in those who had received different vaccines in Sri Lanka. Abs to the receptor binding domain (RBD) of the ancestral (wild type) virus (WT) a...
Gespeichert in:
| Veröffentlicht in: | Immunology 2022-10, Vol.167 (2), p.263-274 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 274 |
|---|---|
| container_issue | 2 |
| container_start_page | 263 |
| container_title | Immunology |
| container_volume | 167 |
| creator | Jeewandara, Chandima Aberathna, Inoka Sepali Danasekara, Saubhagya Gomes, Laksiri Fernando, Suranga Guruge, Dinuka Ranasinghe, Thushali Gunasekera, Banuri Kamaladasa, Achala Kuruppu, Heshan Somathilake, Gayasha Jayamali, Jeewantha Jayathilaka, Deshni Wijayatilake, Helanka Dinesh Kumara Pushpakumara, Pradeep Darshana Harvie, Michael Nimasha, Thashmi Silva, Shiromi Devika Grace Wijayamuni, Ruwan Schimanski, Lisa Rijal, Pramila Tan, Jack Townsend, Alain Ogg, Graham S. Malavige, Gathsaurie Neelika |
| description | To determine the antibody responses elicited by different vaccines against SARS‐CoV‐2, we compared antibody responses in individuals 3 months post‐vaccination in those who had received different vaccines in Sri Lanka. Abs to the receptor binding domain (RBD) of the ancestral (wild type) virus (WT) as well as to variants of concern (VoCs), and ACE2 blocking Abs, were assessed in individuals vaccinated with Moderna (n = 225), Sputnik V (n = 128) or Sputnik light (n = 184) and the results were compared with previously reported data on Sinopharm and AZD1222 vaccinees. A total of 99.5% of Moderna, >94% of AZD1222 or Sputnik V and >70% of Sputnik light, >60% of Sinopharm vaccine recipients, had a positive response to ACE2 blocking antibodies. The ACE2 blocking antibody levels were highest to lowest was Moderna > Sputnik V/AZD1222 (had equal levels) > Sputnik light > Sinopharm. All Moderna recipients had antibodies to the RBD of WT, alpha and beta, while positivity rates for delta variant was 80%. The positivity rates for Sputnik V vaccinees for the WT and VoCs were higher than for AZD1222 vaccinees while those who received Sinopharm had the lowest positivity rates ( |
| doi_str_mv | 10.1111/imm.13535 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9349502</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2681042815</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4435-1252389328e2455f4602a1cbabf627502cf48a9748768309312bf653e75a5bcd3</originalsourceid><addsrcrecordid>eNp1kc9OGzEQhy0EgkA58ALVSlzKYYn_za59QUJpgUhBHGh7tRzjBcOuHexsqtz6CH1GngRDAmor4YvlmU-fZvxD6IDgY5LP0HXdMWHAYAMNCKugpFDVm2iAMZElFRh20G5K9_nJMMA22mFQA4GKDdB4FLqZji4FX4SmmN_ZItt6H26td8bNly_Vxi1sMbr6Of769PsPkcVCG-O8TYXzxXV0xUT7B_0JbTW6TXZ_fe-hH2ffvo8uysnV-Xh0OikN5wxKQoEyIRkVlnKAhleYamKmetpUtAZMTcOFljUXdSUYlozQ3AFma9AwNTdsD52svLN-2tkbY_086lbNout0XKqgnfq3492dug0LJRmX2Z8FX9aCGB57m-aqc8nYttXehj4pWgmCORUEMnr4H3of-ujzeorWRHApBfBMHa0oE0NK0TbvwxCsXgJS-UvVa0CZ_fz39O_kWyIZGK6AX661y49Nanx5uVI-AxNWmLc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2718499854</pqid></control><display><type>article</type><title>Comparison of the immunogenicity of five COVID‐19 vaccines in Sri Lanka</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><source>PubMed Central</source><creator>Jeewandara, Chandima ; Aberathna, Inoka Sepali ; Danasekara, Saubhagya ; Gomes, Laksiri ; Fernando, Suranga ; Guruge, Dinuka ; Ranasinghe, Thushali ; Gunasekera, Banuri ; Kamaladasa, Achala ; Kuruppu, Heshan ; Somathilake, Gayasha ; Jayamali, Jeewantha ; Jayathilaka, Deshni ; Wijayatilake, Helanka Dinesh Kumara ; Pushpakumara, Pradeep Darshana ; Harvie, Michael ; Nimasha, Thashmi ; Silva, Shiromi Devika Grace ; Wijayamuni, Ruwan ; Schimanski, Lisa ; Rijal, Pramila ; Tan, Jack ; Townsend, Alain ; Ogg, Graham S. ; Malavige, Gathsaurie Neelika</creator><creatorcontrib>Jeewandara, Chandima ; Aberathna, Inoka Sepali ; Danasekara, Saubhagya ; Gomes, Laksiri ; Fernando, Suranga ; Guruge, Dinuka ; Ranasinghe, Thushali ; Gunasekera, Banuri ; Kamaladasa, Achala ; Kuruppu, Heshan ; Somathilake, Gayasha ; Jayamali, Jeewantha ; Jayathilaka, Deshni ; Wijayatilake, Helanka Dinesh Kumara ; Pushpakumara, Pradeep Darshana ; Harvie, Michael ; Nimasha, Thashmi ; Silva, Shiromi Devika Grace ; Wijayamuni, Ruwan ; Schimanski, Lisa ; Rijal, Pramila ; Tan, Jack ; Townsend, Alain ; Ogg, Graham S. ; Malavige, Gathsaurie Neelika</creatorcontrib><description>To determine the antibody responses elicited by different vaccines against SARS‐CoV‐2, we compared antibody responses in individuals 3 months post‐vaccination in those who had received different vaccines in Sri Lanka. Abs to the receptor binding domain (RBD) of the ancestral (wild type) virus (WT) as well as to variants of concern (VoCs), and ACE2 blocking Abs, were assessed in individuals vaccinated with Moderna (n = 225), Sputnik V (n = 128) or Sputnik light (n = 184) and the results were compared with previously reported data on Sinopharm and AZD1222 vaccinees. A total of 99.5% of Moderna, >94% of AZD1222 or Sputnik V and >70% of Sputnik light, >60% of Sinopharm vaccine recipients, had a positive response to ACE2 blocking antibodies. The ACE2 blocking antibody levels were highest to lowest was Moderna > Sputnik V/AZD1222 (had equal levels) > Sputnik light > Sinopharm. All Moderna recipients had antibodies to the RBD of WT, alpha and beta, while positivity rates for delta variant was 80%. The positivity rates for Sputnik V vaccinees for the WT and VoCs were higher than for AZD1222 vaccinees while those who received Sinopharm had the lowest positivity rates (<16.7%). The total antibodies to the RBD were highest for the Sputnik V and AZD1222 vaccinees. The Moderna vaccine elicited the highest ACE2 blocking antibody levels followed by Sputnik V/AZD1222, while those who received Sinopharm had the lowest levels. These findings highlight the need for further studies to understand the effects on clinical outcomes.
We found that the seropositivity rates, ACE2 blocking antibody levels and antibodies to the receptor binding domain of variants of concern showed a significant variation between vaccines. The levels of ACE2 blocking antibodies were the highest for Moderna, followed by Sputnik V and AZD1222, followed by the lowest for Sinopharm. These differences in the antibody response to different vaccines may have significant implications in breakthrough infection rates, hospitalization and severe disease in different vaccine recipients.</description><identifier>ISSN: 0019-2805</identifier><identifier>EISSN: 1365-2567</identifier><identifier>DOI: 10.1111/imm.13535</identifier><identifier>PMID: 35751563</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>ACE2 ; Angiotensin-Converting Enzyme 2 ; Antibodies ; Antibodies, Blocking ; Antibodies, Viral ; Blocking antibodies ; ChAdOx1 nCoV-19 ; COVID-19 ; COVID-19 - prevention & control ; COVID-19 Vaccines ; Humans ; Immunogenicity ; Light levels ; memory ; Original ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2 ; Sri Lanka ; vaccination ; Vaccines ; Viruses</subject><ispartof>Immunology, 2022-10, Vol.167 (2), p.263-274</ispartof><rights>2022 The Authors. published by John Wiley & Sons Ltd.</rights><rights>2022 The Authors. Immunology published by John Wiley & Sons Ltd.</rights><rights>2022. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4435-1252389328e2455f4602a1cbabf627502cf48a9748768309312bf653e75a5bcd3</citedby><cites>FETCH-LOGICAL-c4435-1252389328e2455f4602a1cbabf627502cf48a9748768309312bf653e75a5bcd3</cites><orcidid>0000-0002-3334-2811 ; 0000-0001-9201-0449</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349502/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349502/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,1417,1433,27924,27925,45574,45575,46409,46833,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35751563$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jeewandara, Chandima</creatorcontrib><creatorcontrib>Aberathna, Inoka Sepali</creatorcontrib><creatorcontrib>Danasekara, Saubhagya</creatorcontrib><creatorcontrib>Gomes, Laksiri</creatorcontrib><creatorcontrib>Fernando, Suranga</creatorcontrib><creatorcontrib>Guruge, Dinuka</creatorcontrib><creatorcontrib>Ranasinghe, Thushali</creatorcontrib><creatorcontrib>Gunasekera, Banuri</creatorcontrib><creatorcontrib>Kamaladasa, Achala</creatorcontrib><creatorcontrib>Kuruppu, Heshan</creatorcontrib><creatorcontrib>Somathilake, Gayasha</creatorcontrib><creatorcontrib>Jayamali, Jeewantha</creatorcontrib><creatorcontrib>Jayathilaka, Deshni</creatorcontrib><creatorcontrib>Wijayatilake, Helanka Dinesh Kumara</creatorcontrib><creatorcontrib>Pushpakumara, Pradeep Darshana</creatorcontrib><creatorcontrib>Harvie, Michael</creatorcontrib><creatorcontrib>Nimasha, Thashmi</creatorcontrib><creatorcontrib>Silva, Shiromi Devika Grace</creatorcontrib><creatorcontrib>Wijayamuni, Ruwan</creatorcontrib><creatorcontrib>Schimanski, Lisa</creatorcontrib><creatorcontrib>Rijal, Pramila</creatorcontrib><creatorcontrib>Tan, Jack</creatorcontrib><creatorcontrib>Townsend, Alain</creatorcontrib><creatorcontrib>Ogg, Graham S.</creatorcontrib><creatorcontrib>Malavige, Gathsaurie Neelika</creatorcontrib><title>Comparison of the immunogenicity of five COVID‐19 vaccines in Sri Lanka</title><title>Immunology</title><addtitle>Immunology</addtitle><description>To determine the antibody responses elicited by different vaccines against SARS‐CoV‐2, we compared antibody responses in individuals 3 months post‐vaccination in those who had received different vaccines in Sri Lanka. Abs to the receptor binding domain (RBD) of the ancestral (wild type) virus (WT) as well as to variants of concern (VoCs), and ACE2 blocking Abs, were assessed in individuals vaccinated with Moderna (n = 225), Sputnik V (n = 128) or Sputnik light (n = 184) and the results were compared with previously reported data on Sinopharm and AZD1222 vaccinees. A total of 99.5% of Moderna, >94% of AZD1222 or Sputnik V and >70% of Sputnik light, >60% of Sinopharm vaccine recipients, had a positive response to ACE2 blocking antibodies. The ACE2 blocking antibody levels were highest to lowest was Moderna > Sputnik V/AZD1222 (had equal levels) > Sputnik light > Sinopharm. All Moderna recipients had antibodies to the RBD of WT, alpha and beta, while positivity rates for delta variant was 80%. The positivity rates for Sputnik V vaccinees for the WT and VoCs were higher than for AZD1222 vaccinees while those who received Sinopharm had the lowest positivity rates (<16.7%). The total antibodies to the RBD were highest for the Sputnik V and AZD1222 vaccinees. The Moderna vaccine elicited the highest ACE2 blocking antibody levels followed by Sputnik V/AZD1222, while those who received Sinopharm had the lowest levels. These findings highlight the need for further studies to understand the effects on clinical outcomes.
We found that the seropositivity rates, ACE2 blocking antibody levels and antibodies to the receptor binding domain of variants of concern showed a significant variation between vaccines. The levels of ACE2 blocking antibodies were the highest for Moderna, followed by Sputnik V and AZD1222, followed by the lowest for Sinopharm. These differences in the antibody response to different vaccines may have significant implications in breakthrough infection rates, hospitalization and severe disease in different vaccine recipients.</description><subject>ACE2</subject><subject>Angiotensin-Converting Enzyme 2</subject><subject>Antibodies</subject><subject>Antibodies, Blocking</subject><subject>Antibodies, Viral</subject><subject>Blocking antibodies</subject><subject>ChAdOx1 nCoV-19</subject><subject>COVID-19</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 Vaccines</subject><subject>Humans</subject><subject>Immunogenicity</subject><subject>Light levels</subject><subject>memory</subject><subject>Original</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Sri Lanka</subject><subject>vaccination</subject><subject>Vaccines</subject><subject>Viruses</subject><issn>0019-2805</issn><issn>1365-2567</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp1kc9OGzEQhy0EgkA58ALVSlzKYYn_za59QUJpgUhBHGh7tRzjBcOuHexsqtz6CH1GngRDAmor4YvlmU-fZvxD6IDgY5LP0HXdMWHAYAMNCKugpFDVm2iAMZElFRh20G5K9_nJMMA22mFQA4GKDdB4FLqZji4FX4SmmN_ZItt6H26td8bNly_Vxi1sMbr6Of769PsPkcVCG-O8TYXzxXV0xUT7B_0JbTW6TXZ_fe-hH2ffvo8uysnV-Xh0OikN5wxKQoEyIRkVlnKAhleYamKmetpUtAZMTcOFljUXdSUYlozQ3AFma9AwNTdsD52svLN-2tkbY_086lbNout0XKqgnfq3492dug0LJRmX2Z8FX9aCGB57m-aqc8nYttXehj4pWgmCORUEMnr4H3of-ujzeorWRHApBfBMHa0oE0NK0TbvwxCsXgJS-UvVa0CZ_fz39O_kWyIZGK6AX661y49Nanx5uVI-AxNWmLc</recordid><startdate>202210</startdate><enddate>202210</enddate><creator>Jeewandara, Chandima</creator><creator>Aberathna, Inoka Sepali</creator><creator>Danasekara, Saubhagya</creator><creator>Gomes, Laksiri</creator><creator>Fernando, Suranga</creator><creator>Guruge, Dinuka</creator><creator>Ranasinghe, Thushali</creator><creator>Gunasekera, Banuri</creator><creator>Kamaladasa, Achala</creator><creator>Kuruppu, Heshan</creator><creator>Somathilake, Gayasha</creator><creator>Jayamali, Jeewantha</creator><creator>Jayathilaka, Deshni</creator><creator>Wijayatilake, Helanka Dinesh Kumara</creator><creator>Pushpakumara, Pradeep Darshana</creator><creator>Harvie, Michael</creator><creator>Nimasha, Thashmi</creator><creator>Silva, Shiromi Devika Grace</creator><creator>Wijayamuni, Ruwan</creator><creator>Schimanski, Lisa</creator><creator>Rijal, Pramila</creator><creator>Tan, Jack</creator><creator>Townsend, Alain</creator><creator>Ogg, Graham S.</creator><creator>Malavige, Gathsaurie Neelika</creator><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QR</scope><scope>7T5</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3334-2811</orcidid><orcidid>https://orcid.org/0000-0001-9201-0449</orcidid></search><sort><creationdate>202210</creationdate><title>Comparison of the immunogenicity of five COVID‐19 vaccines in Sri Lanka</title><author>Jeewandara, Chandima ; Aberathna, Inoka Sepali ; Danasekara, Saubhagya ; Gomes, Laksiri ; Fernando, Suranga ; Guruge, Dinuka ; Ranasinghe, Thushali ; Gunasekera, Banuri ; Kamaladasa, Achala ; Kuruppu, Heshan ; Somathilake, Gayasha ; Jayamali, Jeewantha ; Jayathilaka, Deshni ; Wijayatilake, Helanka Dinesh Kumara ; Pushpakumara, Pradeep Darshana ; Harvie, Michael ; Nimasha, Thashmi ; Silva, Shiromi Devika Grace ; Wijayamuni, Ruwan ; Schimanski, Lisa ; Rijal, Pramila ; Tan, Jack ; Townsend, Alain ; Ogg, Graham S. ; Malavige, Gathsaurie Neelika</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4435-1252389328e2455f4602a1cbabf627502cf48a9748768309312bf653e75a5bcd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>ACE2</topic><topic>Angiotensin-Converting Enzyme 2</topic><topic>Antibodies</topic><topic>Antibodies, Blocking</topic><topic>Antibodies, Viral</topic><topic>Blocking antibodies</topic><topic>ChAdOx1 nCoV-19</topic><topic>COVID-19</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 Vaccines</topic><topic>Humans</topic><topic>Immunogenicity</topic><topic>Light levels</topic><topic>memory</topic><topic>Original</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Sri Lanka</topic><topic>vaccination</topic><topic>Vaccines</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jeewandara, Chandima</creatorcontrib><creatorcontrib>Aberathna, Inoka Sepali</creatorcontrib><creatorcontrib>Danasekara, Saubhagya</creatorcontrib><creatorcontrib>Gomes, Laksiri</creatorcontrib><creatorcontrib>Fernando, Suranga</creatorcontrib><creatorcontrib>Guruge, Dinuka</creatorcontrib><creatorcontrib>Ranasinghe, Thushali</creatorcontrib><creatorcontrib>Gunasekera, Banuri</creatorcontrib><creatorcontrib>Kamaladasa, Achala</creatorcontrib><creatorcontrib>Kuruppu, Heshan</creatorcontrib><creatorcontrib>Somathilake, Gayasha</creatorcontrib><creatorcontrib>Jayamali, Jeewantha</creatorcontrib><creatorcontrib>Jayathilaka, Deshni</creatorcontrib><creatorcontrib>Wijayatilake, Helanka Dinesh Kumara</creatorcontrib><creatorcontrib>Pushpakumara, Pradeep Darshana</creatorcontrib><creatorcontrib>Harvie, Michael</creatorcontrib><creatorcontrib>Nimasha, Thashmi</creatorcontrib><creatorcontrib>Silva, Shiromi Devika Grace</creatorcontrib><creatorcontrib>Wijayamuni, Ruwan</creatorcontrib><creatorcontrib>Schimanski, Lisa</creatorcontrib><creatorcontrib>Rijal, Pramila</creatorcontrib><creatorcontrib>Tan, Jack</creatorcontrib><creatorcontrib>Townsend, Alain</creatorcontrib><creatorcontrib>Ogg, Graham S.</creatorcontrib><creatorcontrib>Malavige, Gathsaurie Neelika</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jeewandara, Chandima</au><au>Aberathna, Inoka Sepali</au><au>Danasekara, Saubhagya</au><au>Gomes, Laksiri</au><au>Fernando, Suranga</au><au>Guruge, Dinuka</au><au>Ranasinghe, Thushali</au><au>Gunasekera, Banuri</au><au>Kamaladasa, Achala</au><au>Kuruppu, Heshan</au><au>Somathilake, Gayasha</au><au>Jayamali, Jeewantha</au><au>Jayathilaka, Deshni</au><au>Wijayatilake, Helanka Dinesh Kumara</au><au>Pushpakumara, Pradeep Darshana</au><au>Harvie, Michael</au><au>Nimasha, Thashmi</au><au>Silva, Shiromi Devika Grace</au><au>Wijayamuni, Ruwan</au><au>Schimanski, Lisa</au><au>Rijal, Pramila</au><au>Tan, Jack</au><au>Townsend, Alain</au><au>Ogg, Graham S.</au><au>Malavige, Gathsaurie Neelika</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of the immunogenicity of five COVID‐19 vaccines in Sri Lanka</atitle><jtitle>Immunology</jtitle><addtitle>Immunology</addtitle><date>2022-10</date><risdate>2022</risdate><volume>167</volume><issue>2</issue><spage>263</spage><epage>274</epage><pages>263-274</pages><issn>0019-2805</issn><eissn>1365-2567</eissn><abstract>To determine the antibody responses elicited by different vaccines against SARS‐CoV‐2, we compared antibody responses in individuals 3 months post‐vaccination in those who had received different vaccines in Sri Lanka. Abs to the receptor binding domain (RBD) of the ancestral (wild type) virus (WT) as well as to variants of concern (VoCs), and ACE2 blocking Abs, were assessed in individuals vaccinated with Moderna (n = 225), Sputnik V (n = 128) or Sputnik light (n = 184) and the results were compared with previously reported data on Sinopharm and AZD1222 vaccinees. A total of 99.5% of Moderna, >94% of AZD1222 or Sputnik V and >70% of Sputnik light, >60% of Sinopharm vaccine recipients, had a positive response to ACE2 blocking antibodies. The ACE2 blocking antibody levels were highest to lowest was Moderna > Sputnik V/AZD1222 (had equal levels) > Sputnik light > Sinopharm. All Moderna recipients had antibodies to the RBD of WT, alpha and beta, while positivity rates for delta variant was 80%. The positivity rates for Sputnik V vaccinees for the WT and VoCs were higher than for AZD1222 vaccinees while those who received Sinopharm had the lowest positivity rates (<16.7%). The total antibodies to the RBD were highest for the Sputnik V and AZD1222 vaccinees. The Moderna vaccine elicited the highest ACE2 blocking antibody levels followed by Sputnik V/AZD1222, while those who received Sinopharm had the lowest levels. These findings highlight the need for further studies to understand the effects on clinical outcomes.
We found that the seropositivity rates, ACE2 blocking antibody levels and antibodies to the receptor binding domain of variants of concern showed a significant variation between vaccines. The levels of ACE2 blocking antibodies were the highest for Moderna, followed by Sputnik V and AZD1222, followed by the lowest for Sinopharm. These differences in the antibody response to different vaccines may have significant implications in breakthrough infection rates, hospitalization and severe disease in different vaccine recipients.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>35751563</pmid><doi>10.1111/imm.13535</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-3334-2811</orcidid><orcidid>https://orcid.org/0000-0001-9201-0449</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0019-2805 |
| ispartof | Immunology, 2022-10, Vol.167 (2), p.263-274 |
| issn | 0019-2805 1365-2567 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9349502 |
| source | MEDLINE; Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection); PubMed Central |
| subjects | ACE2 Angiotensin-Converting Enzyme 2 Antibodies Antibodies, Blocking Antibodies, Viral Blocking antibodies ChAdOx1 nCoV-19 COVID-19 COVID-19 - prevention & control COVID-19 Vaccines Humans Immunogenicity Light levels memory Original SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Sri Lanka vaccination Vaccines Viruses |
| title | Comparison of the immunogenicity of five COVID‐19 vaccines in Sri Lanka |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T20%3A57%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20the%20immunogenicity%20of%20five%20COVID%E2%80%9019%20vaccines%20in%20Sri%20Lanka&rft.jtitle=Immunology&rft.au=Jeewandara,%20Chandima&rft.date=2022-10&rft.volume=167&rft.issue=2&rft.spage=263&rft.epage=274&rft.pages=263-274&rft.issn=0019-2805&rft.eissn=1365-2567&rft_id=info:doi/10.1111/imm.13535&rft_dat=%3Cproquest_pubme%3E2681042815%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2718499854&rft_id=info:pmid/35751563&rfr_iscdi=true |